Compare iShares Self-Driving EV and Tech (IDRV) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares Self-Driving EV and Tech trades at $33.26 (market cap $264.50M), while Royalty Pharma plc Class A Ordinary Shares trades at $57 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 95.5× iShares Self-Driving EV and Tech's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares Self-Driving EV and Tech pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Self-Driving EV and Tech for 73 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| IDRV | RPRX | |
|---|---|---|
Market Cap | $264.50M | $25.27B |
Volume | 48,021 | 3,671,183 |
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $63.96 |
52-Week Low | $32.68 | $35.44 |
Typical Hold Time | 73 Days | 0 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
